Co-Founder, Vice President of Biomarker Research
United States of America
Eric Thompson is Paradigm’s Vice President of Biomarker Research. Dr. Thompson has extensive experience in the fields of pharmacology, toxicology, and molecular biology, and spearheaded the development of Paradigm’s proprietary evidence-based medicine engine. Considered an expert in translating biomarkers from research literature to clinical practice, Dr. Thompson formed and directs the evidence based medicine group responsible for content of the Paradigm PCDx test. Eric also is responsible for working on business development efforts related to biomarker strategy and custom assay development with BioPharma clients. Prior to joining Paradigm, he had years of experience managing and providing consulting services regarding biomarker research across a number of different organizations, including serving as Assistant Director of the Predictive Safety Testing Consortium (PSTC) at The Critical Path Institute. Dr. Thompson has a PhD in Pharmacology and Toxicology from the University of Arizona and did his Research Fellowship at the Mayo Clinic, Scottsdale.
Genetics, clinical trials, cancer